Patent classifications
C12Q2561/109
DETECTION OF DRUG-RESISTANT MYCOPLASMA GENITALIUM
Provided are methods, compositions and systems for detecting the presence or absence of nucleic acid targets, such as nucleic acids of macrolide-resistant Mycoplasma genitalium. In one embodiment, real-time Ct values determined for a wild-type sequence and for a drug resistance marker, each on an opposite strand of the same amplification product, are compared to determine the presence or absence of the drug resistance marker in nucleic acids of a test sample.
DETECTION OF DRUG-RESISTANT MYCOPLASMA GENITALIUM
Provided are methods, compositions and systems for detecting the presence or absence of nucleic acid targets, such as nucleic acids of macrolide-resistant Mycoplasma genitalium. In one embodiment, real-time Ct values determined for a wild-type sequence and for a drug resistance marker, each on an opposite strand of the same amplification product, are compared to determine the presence or absence of the drug resistance marker in nucleic acids of a test sample.
Omega amplification
The present disclosure provides compositions, methods and kits for Omega amplification technologies. In addition, the present disclosure provides compositions, methods and kits for universal FQ probe and for G-quadruplex detection methods for use in isothermal amplification technologies.
Omega amplification
The present disclosure provides compositions, methods and kits for Omega amplification technologies. In addition, the present disclosure provides compositions, methods and kits for universal FQ probe and for G-quadruplex detection methods for use in isothermal amplification technologies.
Multiplexed Kras Mutation Detection Assay
Provided herein is reagent mixture comprising multiplexed amplification reagents and flap assay reagents for detecting, in a single reaction, mutant copies of the KRAS gene that contain any of the 34A, 34C, 34T, 35A, 35C, 35T or 38A point mutations. Methods that employ the reagent mix and kits for performing the same are also provided.
Multiplexed Kras Mutation Detection Assay
Provided herein is reagent mixture comprising multiplexed amplification reagents and flap assay reagents for detecting, in a single reaction, mutant copies of the KRAS gene that contain any of the 34A, 34C, 34T, 35A, 35C, 35T or 38A point mutations. Methods that employ the reagent mix and kits for performing the same are also provided.
METHYLATED CONTROL DNA
Provided herein is technology relating compositions and methods for analysis of methylated DNA from a subject. The technology also relates to use of endogenous methylated DNAs as internal controls for marker gene methylation assays.
METHYLATED CONTROL DNA
Provided herein is technology relating compositions and methods for analysis of methylated DNA from a subject. The technology also relates to use of endogenous methylated DNAs as internal controls for marker gene methylation assays.
DETECTION OF TARGET NUCLEIC ACID SEQUENCES BY PTO CLEAVAGE AND EXTENSION ASSAY
The present invention relates to the detection of a target nucleic acid sequence by a PTOCE (PTO Cleavage and Extension) assay. The present invention detects a target nucleic acid sequence in which the PTO (Probing and Tagging Oligonucleotide) hybridized with the target nucleic acid sequence is cleaved to release a fragment and the fragment is hybridized with the CTO (Capturing and Templating Oligonucleotide) to form an extended duplex, followed by detecting the presence of the extended duplex. The extended duplex provides signals (generation, increase, extinguishment or decrease of signals) from labels indicating the presence of the extended duplex and has adjustable T.sub.m value, which are well adoptable for detection of the presence of the target nucleic acid sequence.
DETECTION OF TARGET NUCLEIC ACID SEQUENCES BY PTO CLEAVAGE AND EXTENSION ASSAY
The present invention relates to the detection of a target nucleic acid sequence by a PTOCE (PTO Cleavage and Extension) assay. The present invention detects a target nucleic acid sequence in which the PTO (Probing and Tagging Oligonucleotide) hybridized with the target nucleic acid sequence is cleaved to release a fragment and the fragment is hybridized with the CTO (Capturing and Templating Oligonucleotide) to form an extended duplex, followed by detecting the presence of the extended duplex. The extended duplex provides signals (generation, increase, extinguishment or decrease of signals) from labels indicating the presence of the extended duplex and has adjustable T.sub.m value, which are well adoptable for detection of the presence of the target nucleic acid sequence.